ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements
Tarsons Products will hold a board meeting on November 12, 2026 to consider unaudited standalone and consolidated half-year results for September 2026. The trading window is closed from October 1 to November 14, 2026.
Tarsons Products Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Tarsons Products Limited re-appointed Sanjive Sehgal as Executive Director following his retirement by rotation. This filing updates his directorial status.
Tarsons Products Limited held its 43rd Annual General Meeting on September 24, 2026, through video conferencing. Shareholders discussed financial statements and approved various resolutions.
Tarsons Products clarified that the recent increase in its share trading volume is market-driven, and no undisclosed material information or price-sensitive details exist.
Tarsons Products Ltd sent a letter to shareholders without registered emails, providing the web link to access the Annual Report and Notice of the 43rd AGM.
Tarsons Products Ltd scheduled its 43rd Annual General Meeting for September 24, 2026. Key agenda items include adopting FY2025-26 financials and approving material related-party transactions.
Tarsons Products Limited has submitted its Annual Report for the financial year ended March 31, 2026. The report includes highlights, statutory reports, and audited financial statements.
Tarsons Products Ltd filed its quarterly shareholding pattern for the period ended June 30, 2025, as mandated by SEBI regulations.
Tarsons delivered record Q1 revenue growth of 21% YoY, yet profitability is severely squeezed by a 25-50% spike in raw material costs and heavy depreciation from new capex.
Tarsons reported 21% YoY consolidated revenue growth in Q1 FY27, reaching ₹110.2 cr, driven by domestic and export recovery despite margin pressure from raw material costs and new facility expenses.
Tarsons Products Ltd reported revenue from operations of ₹110.2 Cr (+20.6% YoY) and a net loss of ₹1.4 Cr for Q1 FY27.
Tarsons Products Limited will hold a board meeting on August 10, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Tarsons Products Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI Regulation 31(1)(b) requirements.
Mr. Subhra Shankar Bose resigned as Human Resource Head of Tarsons Products Ltd. The company has acknowledged his resignation effective June 15, 2026.
Tarsons Products completed a ₹6.12 Crore equity infusion into its wholly-owned subsidiary, Tarsons Lifescience Pte Ltd. This investment fulfills a previously approved 3 million Euro mandate.
Tarsons Products Limited completed a second tranche investment of EUR 552,000 (₹6.07 Crore) in its Singapore subsidiary. Funds will facilitate bank loan repayment and operational requirements.
Tarsons reported record quarterly revenue of ₹121cr (Q4 FY26). Management is focused on ramping up newly commissioned bioprocess and cell culture facilities to drive long-term operating leverage.
Tarsons reported record quarterly revenue but margins were squeezed by raw material spikes and new plant costs.
Tarsons reported FY26 consolidated revenue growth of 8% to ₹422.5 cr, while PAT declined 48% to ₹15.5 cr due to high depreciation and finance costs from new facility capitalizations.
Tarsons Products Ltd reported revenue from operations of ₹120.9 Cr (+7.3% YoY) and net profit of ₹4.2 Cr (-58.8% YoY) for Q4 FY26.
Tarsons Products Limited approved its audited financial results for the year ended March 31, 2026. The board also re-appointed M/s. Grant Thornton Bharat LLP as internal auditors.
Tarsons Products submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no adverse observations.
Tarsons Products scheduled a board meeting on May 22, 2026, to approve annual audited financial results. The trading window remains closed for 48 hours post-declaration.
Tarsons Products Limited has appointed Mr. Mani Kalyan Dusi to a senior leadership position. Mr. Dusi brings over 18 years of experience from Merck Life Science and Thermo-Fisher Scientific. His expertise in commercial strategy and APAC market expansion is expected to drive operational excellence and business growth for the company.
Tarsons Products Limited has appointed Mr. Mani Kalyan Dusi as Head – Revenue (India & APAC). Designated as Senior Management Personnel, he brings over 18 years of experience from Merck Life Science and Thermo-Fisher Scientific. He is expected to join the company by May 20, 2026.
Tarsons Products Limited has completed a ₹3.24 Crore equity infusion into its wholly-owned subsidiary, Tarsons Lifescience Pte Ltd. This transaction follows a board approval from February 2026 for a total planned investment of 3 million Euros.
Tarsons Products Ltd completed a ₹3.21 Crore (EUR 300,000) equity investment in its Singapore-based subsidiary, Tarsons Life Science Pte. Ltd. The capital will fund loan repayments and general corporate expenses.
Tarsons Products Ltd has appointed Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director for five years, effective February 06, 2026. Shareholders approved the appointment via postal ballot. Mr. Kriplani, a Chartered Accountant with 29 years of experience, currently leads M&A and international tax at Serum Institute of India.
Tarsons Products Limited announced the successful passage of a special resolution via postal ballot for the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director. The resolution was passed with a 99.99% majority of votes polled. The voting process was conducted electronically and concluded on April 06, 2026.